

ABSTRACT

The present invention relates to novel
classes of compounds which are inhibitors of
interleukin-1 β converting enzyme. The ICE inhibitors
of this invention are characterized by specific
structural and physicochemical features. This
invention also relates to pharmaceutical compositions
comprising these compounds. The compounds and
pharmaceutical compositions of this invention are
particularly well suited for inhibiting ICE activity
and consequently, may be advantageously used as
agents against interleukin-1 mediated diseases,
including inflammatory diseases, autoimmune diseases
and neurodegenerative diseases. This invention also
relates to methods for inhibiting ICE activity and
methods for treating interleukin-1 mediated diseases
using the compounds and compositions of this
invention.

123500 27 0960